DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

November is National Diabetes Month, and Durango’s Bruce Moss is proving diabetes doesn’t have to slow you down. At 67, he ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst Richard Newitter lowered the firm’s price target on DexCom to $94 from $102 ...

Morgan Stanley lowered the firm’s price target on DexCom (DXCM) to $63 from $89 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for real-time, ...

Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.

The correction is one of the largest in Abbott's recent continuous glucose monitor business, which dominates the global ...

Investing.com - BTIG lowered its price target on DexCom (NASDAQ:DXCM) to $85 from $109 on Friday, while maintaining a Buy rating following the company’s third-quarter earnings report. The new target ...

DexCom simultaneously lowered its gross margin and adjusted EBITDA guidance as ongoing quality-related costs continue to impact profitability. For investors seeking deeper insights, InvestingPro ...